AuthorCitation

Faculty Opinions recommendation of Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726295007.793517173

Faculty Opinions recommendation of Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726118899.793517175

Faculty Opinions recommendation of Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725984091.793517172

Faculty Opinions recommendation of Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725927630.793517174

Faculty Opinions recommendation of Chimeric antigen receptor T cells for sustained remissions in leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.722007528.793517176

Faculty Opinions recommendation of Mitigating the toxic effects of anticancer immunotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718245866.793517171

Faculty Opinions recommendation of 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725829908.793517170

Faculty Opinions recommendation of Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718373311.793517169

Faculty Opinions recommendation of Cancer statistics, 2016.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726071516.793517164

Faculty Opinions recommendation of Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725432487.793517165

Ansell, Stephen M.

Citations 952

Faculty Opinions recommendation of Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant.

Faculty Opinions recommendation of Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Faculty Opinions recommendation of Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders.

Faculty Opinions recommendation of Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Faculty Opinions recommendation of Chimeric antigen receptor T cells for sustained remissions in leukemia.

Faculty Opinions recommendation of Mitigating the toxic effects of anticancer immunotherapy.

Faculty Opinions recommendation of 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Faculty Opinions recommendation of Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.

Faculty Opinions recommendation of Cancer statistics, 2016.

Faculty Opinions recommendation of Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.